Type 2 Low Biomarker Stability and Exacerbations in Severe Uncontrolled Asthma

We investigated the stability of T2 low status, based on levels biomarkers, and exacerbation rates in non-T2 asthma from clinical retrospective data severe uncontrolled patients. Knowledge biomarker profile is sparse uncharted. Secondary care patients with at least two blood eosinophil counts (BEC) fractional exhaled nitric oxide (FeNO) measured for determination type 2 inflammation status were evaluated a follow-up period 4 years. Patients stratified into four groups: low150 (n = 31; BEC < 150 cells/µL FeNO 25 ppb), 138; > and/or low300 66; 300 103; ppb). Exacerbation requiring hospital care, cumulative OCS ICS doses assessed during follow-up. Among asthma, 18% 31) identified as low150, 39% 66) low300. In these groups, was stable 55% 11) 72% 33) measures. different between 19.7 [95% CI: 4.3–45.6] vs. 8.4 [4.7–13.0] per 100 patient-years. are useful biomarkers identifying showing up to Repeated monitoring essential treating asthma.